The COVID-19 pandemic has emphasized the critical need for rapid development and validation of effective treatments and vaccines. Advanced monitoring technologies, such as emkaPACK, play a crucial role in preclinical safety pharmacology and toxicology studies, ensuring the safety and efficacy of new therapeutics.
This application note reviews the significant contributions of emkaPACK in the research and development of Olgotrelvir, the ZF2001 vaccine, and nebulized SARS-CoV-2 neutralizing antibodies.
